Skip to main content

Table 5 Descriptive Data for LVEF

From: A randomized, double-blind, phase III, non-inferiority clinical trial comparing the efficacy and safety of TA4415V (a proposed Trastuzumab biosimilar) and Herceptin (Trastuzumab reference product) in HER2-positive early-stage breast Cancer patients

Visit and Statistic TA4415V Reference trastuzumab
Baseline   Change from Baseline   Change from Baseline
 Mean (95% CI) 57.94 (56.91,59.03)   56.92 (55.42,58.41)  
 Median (Range) 60 (55,60)   55 (55,60)  
Visit 5
 Mean (95% CI) 55.58 (56.72,58.43) 0.30 (− 0.92,1.52) 55.63 (54.10,57.16) 1.92 (− 0.02,3.896)
 Median (Range) 58.25 (55,60) 0 (0,1) 55 (55,60) 0 (− 1.25,5)
Visit 9
 Mean (95% CI) 56.83 (55.40,58.26) 0.39 (−0.89,1.67) 55.02 (52.98,57.05) 1.39 (−0.54,5.22)
 Median (Range) 57.5 (55,60) 0 (−2.5,2.5) 55 (55,57.5) 0 (−1,5)